Prolonged response to oral gefitinib, cyclophophamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: A case report

Alberto Donfrancesco, Alessandro Jenkner, Maria Antonietta De Ioris, Ilaria Ilari, Aurora Castellano, Clementina De Laurentis, Maria Carmen Garganese, Giuseppe Maria Milano, Carlo Dominici

Research output: Contribution to journalArticlepeer-review

Abstract

A girl with metastatic neuroblastoma diagnosed at 4 years of age experienced an early disseminated relapse after high-dose chemotherapy. After reinduction, compassionate treatment with gefitinib (250 mg/d fixed dose) with oral topotecan (0.8 mg/m/d) and cyclophosphamide (50 mg/m/d) for 14 consecutive days, each course repeated every 28 days, was administered. Complete marrow clearance and metaiodobenzylguanidine response were achieved after 4 courses. After the first course, topotecan and cyclophosphamide were reduced by 25% for grade 4 hematologic toxicity. Subsequent courses were well tolerated. The girl remained progression free for 27 months. This combination may represent a viable therapeutic option and deserves further evaluation in resistant neuroblastoma.

Original languageEnglish
Pages (from-to)799-803
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume29
Issue number11
DOIs
Publication statusPublished - Nov 2007

Keywords

  • Epidermal growth factor receptor (EGFR)
  • Neuroblastoma
  • Oral chemotherapy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Fingerprint

Dive into the research topics of 'Prolonged response to oral gefitinib, cyclophophamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: A case report'. Together they form a unique fingerprint.

Cite this